Secondary Analysis of Treatment Effect Heterogeneity of priovi in Borderline Personality Disorder

The digital therapeutic priovi has small average effects for borderline personality disorder (BPD). In this preregistered secondary analysis, we aimed to explore the heterogeneity and potential moderators of these effects. Adults received priovi plus treatment as usual or treatment as usual alone. At the 3-month primary endpoint (N = 528), model-based recursive partitioning showed heterogeneous effects on Borderline Symptom List-23 (BSL-23) change (p = 0.022) and on clinically relevant response (p = 0.007). Benefit was larger at higher baseline symptom load: a representative tree split on Pati

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.